Romiplostim for secondary thrombocytopenia following allogeneic stem cell transplantation in children

• Published in: International journal of hematology Vol. 102; no. 5; pp. 626 - 632
• Main Authors: Maximova, Natalia, Zanon, D., Rovere, F., Maestro, A., Schillani, G., Paparazzo, R.
• Format: Journal Article
• Language: English
• Published: Tokyo Springer Japan 01-11-2015; Springer Nature B.V
• Subjects: Adolescent; Allografts; Case Report; Child; Female; Hematology; Hematopoietic Stem Cell Transplantation; Humans; Male; Medicine; Medicine & Public Health; Oncology; Platelet Count; Receptors, Fc - administration & dosage; Recombinant Fusion Proteins - administration & dosage; Thrombocytopenia - blood; Thrombocytopenia - drug therapy; Thrombocytopenia - etiology; Thrombopoietin - administration & dosage; Romiplostim; Virus infection; Pediatric patients; Secondary failure of platelet recovery
• ISSN: 0925-5710; 1865-3774
• DOI: 10.1007/s12185-015-1821-1

The outcome of romiplostim for secondary failure of platelet recovery (SFPR) was investigated in children who had undergone hematopoietic stem cell transplantation (HSCT). Seven transfusion-dependent pediatric patients (median age 11 years), with platelet counts below 10 × 10
9
/L, received four weekly doses of subcutaneous romiplostim to treat SFPR developed after HSCT. All patients, except one (patient 4), became platelet transfusion-independent in the second week from the beginning of treatment and no patient needed to discontinue drug treatment because of adverse events. Romiplostim could represent a beneficial first-line treatment, but further studies are required.